This amino acid may help the body fight tumors and viral infections
medicalxpress - The amino acid arginine helps keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes. It's produced by our bodies and found in common high-protein foods. Low levels of arginine are associated with a…
AI Summary: New research implicates the amino acid histidine in modulating immune and tumor biology, suggesting it may enhance anti-tumor responses and antiviral defenses in preclinical studies. Scientists report mechanistic insights that could inform future therapeutic strategies, although translation to patients will require careful testing—because promising mouse data still need to pass the human audit.
Most breastfeeding mothers take medication, but many are making decisions without good information
medicalxpress - When a woman who is breastfeeding develops an infection or a flare of a chronic condition, she faces a decision that sounds simple but rarely is: Should she take the medication to treat her condition?
AI Summary: Surveys and reports show a majority of breastfeeding mothers use medications but often make decisions without adequate, evidence-based clinical guidance. The findings underline gaps in provider counseling and accessible information, urging health systems to improve communication so lactating patients can safely balance treatment needs with breastfeeding goals without needless anxiety.
FDA approves Simtriyo for treating ADHD in children and adults
medicalxpress - The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
AI Summary: The FDA granted approval for Simtriyo to treat attention‑deficit/hyperactivity disorder in children and adults, adding a new prescription option to the ADHD toolkit. Regulators highlighted efficacy and safety data supporting the decision; clinicians and patients will now weigh the drug’s profile against existing therapies as rollout and coverage decisions play out.